The tumor suppressor function of STAT1 in breast cancer

References

• Schindler C, Levy DE, Decker T. JAK-STAT signaling: from interferons to cytokines. J Biol Chem 2007; 282:20059 - 63; http://dx.doi.org/10.1074/jbc.R700016200; PMID: 17502367
   PubMed Web of Science ®Google Scholar
• Stark GR, Darnell JE Jr.. The JAK-STAT pathway at twenty. Immunity 2012; 36:503 - 14; http://dx.doi.org/10.1016/j.immuni.2012.03.013; PMID: 22520844
   PubMed Web of Science ®Google Scholar
• Wenta N, Strauss H, Meyer S, Vinkemeier U. Tyrosine phosphorylation regulates the partitioning of STAT1 between different dimer conformations. Proc Natl Acad Sci U S A 2008; 105:9238 - 43; http://dx.doi.org/10.1073/pnas.0802130105; PMID: 18591661
   PubMed Web of Science ®Google Scholar
• Zhong M, Henriksen MA, Takeuchi K, Schaefer O, Liu B, ten Hoeve J, et al. Implications of an antiparallel dimeric structure of nonphosphorylated STAT1 for the activation-inactivation cycle. Proc Natl Acad Sci U S A 2005; 102:3966 - 71; http://dx.doi.org/10.1073/pnas.0501063102; PMID: 15753310
   PubMed Web of Science ®Google Scholar
• Regis G, Pensa S, Boselli D, Novelli F, Poli V. Ups and downs: the STAT1:STAT3 seesaw of Interferon and gp130 receptor signalling. Semin Cell Dev Biol 2008; 19:351 - 9; http://dx.doi.org/10.1016/j.semcdb.2008.06.004; PMID: 18620071
   PubMed Web of Science ®Google Scholar
• Krämer OH, Heinzel T. Phosphorylation-acetylation switch in the regulation of STAT1 signaling. Mol Cell Endocrinol 2010; 315:40 - 8; http://dx.doi.org/10.1016/j.mce.2009.10.007; PMID: 19879327
   PubMed Web of Science ®Google Scholar
• Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A 1998; 95:7556 - 61; http://dx.doi.org/10.1073/pnas.95.13.7556; PMID: 9636188
   PubMed Web of Science ®Google Scholar
• Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006; 6:836 - 48; http://dx.doi.org/10.1038/nri1961; PMID: 17063185
   PubMed Web of Science ®Google Scholar
• Chin YE, Kitagawa M, Su WC, You ZH, Iwamoto Y, Fu XY. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. Science 1996; 272:719 - 22; http://dx.doi.org/10.1126/science.272.5262.719; PMID: 8614832
   PubMed Web of Science ®Google Scholar
• Ramana CV, Grammatikakis N, Chernov M, Nguyen H, Goh KC, Williams BR, et al. Regulation of c-myc expression by IFN-gamma through Stat1-dependent and -independent pathways. EMBO J 2000; 19:263 - 72; http://dx.doi.org/10.1093/emboj/19.2.263; PMID: 10637230
   PubMed Web of Science ®Google Scholar
• Chin YE, Kitagawa M, Kuida K, Flavell RA, Fu XY. Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis. Mol Cell Biol 1997; 17:5328 - 37; PMID: 9271410
   PubMed Web of Science ®Google Scholar
• Kumar A, Commane M, Flickinger TW, Horvath CM, Stark GR. Defective TNF-alpha-induced apoptosis in STAT1-null cells due to low constitutive levels of caspases. Science 1997; 278:1630 - 2; http://dx.doi.org/10.1126/science.278.5343.1630; PMID: 9374464
   PubMed Web of Science ®Google Scholar
• Kim HS, Lee MS. STAT1 as a key modulator of cell death. Cell Signal 2007; 19:454 - 65; http://dx.doi.org/10.1016/j.cellsig.2006.09.003; PMID: 17085014
   PubMed Web of Science ®Google Scholar
• Huang S, Bucana CD, Van Arsdall M, Fidler IJ. Stat1 negatively regulates angiogenesis, tumorigenicity and metastasis of tumor cells. Oncogene 2002; 21:2504 - 12; http://dx.doi.org/10.1038/sj.onc.1205341; PMID: 11971185
   PubMed Web of Science ®Google Scholar
• Yu H, Jove R. The STATs of cancer--new molecular targets come of age. Nat Rev Cancer 2004; 4:97 - 105; http://dx.doi.org/10.1038/nrc1275; PMID: 14964307
   PubMed Web of Science ®Google Scholar
• Bromberg J. Stat proteins and oncogenesis. J Clin Invest 2002; 109:1139 - 42; PMID: 11994401
   PubMed Web of Science ®Google Scholar
• Wang S, Koromilas AE. Stat1 is an inhibitor of Ras-MAPK signaling and Rho small GTPase expression with implications in the transcriptional signature of Ras transformed cells. Cell Cycle 2009; 8:2070 - 9; http://dx.doi.org/10.4161/cc.8.13.8891; PMID: 19502801
   PubMed Web of Science ®Google Scholar
• Wang S, Raven JF, Durbin JE, Koromilas AE. Stat1 phosphorylation determines Ras oncogenicity by regulating p27 kip1. PLoS One 2008; 3:e3476; http://dx.doi.org/10.1371/journal.pone.0003476; PMID: 18941537
   PubMed Web of Science ®Google Scholar
• Wang S, Raven JF, Koromilas AE. STAT1 represses Skp2 gene transcription to promote p27Kip1 stabilization in Ras-transformed cells. Mol Cancer Res 2010; 8:798 - 805; http://dx.doi.org/10.1158/1541-7786.MCR-10-0027; PMID: 20407011
   PubMed Web of Science ®Google Scholar
• Kovacic B, Stoiber D, Moriggl R, Weisz E, Ott RG, Kreibich R, et al. STAT1 acts as a tumor promoter for leukemia development. Cancer Cell 2006; 10:77 - 87; http://dx.doi.org/10.1016/j.ccr.2006.05.025; PMID: 16843267
   PubMed Web of Science ®Google Scholar
• Watson CJ. Stat transcription factors in mammary gland development and tumorigenesis. J Mammary Gland Biol Neoplasia 2001; 6:115 - 27; http://dx.doi.org/10.1023/A:1009524817155; PMID: 11467447
   PubMed Web of Science ®Google Scholar
• Widschwendter A, Tonko-Geymayer S, Welte T, Daxenbichler G, Marth C, Doppler W. Prognostic significance of signal transducer and activator of transcription 1 activation in breast cancer. Clin Cancer Res 2002; 8:3065 - 74; PMID: 12374673
   PubMed Web of Science ®Google Scholar
• Yau C, Esserman L, Moore DH, Waldman F, Sninsky J, Benz CC. A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer. Breast Cancer Res 2010; 12:R85; http://dx.doi.org/10.1186/bcr2753; PMID: 20946665
   PubMed Web of Science ®Google Scholar
• Klover PJ, Muller WJ, Robinson GW, Pfeiffer RM, Yamaji D, Hennighausen L. Loss of STAT1 from mouse mammary epithelium results in an increased Neu-induced tumor burden. Neoplasia 2010; 12:899 - 905; PMID: 21076615
   PubMed Web of Science ®Google Scholar
• Raven JF, Williams V, Wang S, Tremblay ML, Muller WJ, Durbin JE, et al. Stat1 is a suppressor of ErbB2/Neu-mediated cellular transformation and mouse mammary gland tumor formation. Cell Cycle 2011; 10:794 - 804; http://dx.doi.org/10.4161/cc.10.5.14956; PMID: 21311224
   PubMed Web of Science ®Google Scholar
• Chan SR, Vermi W, Luo J, Lucini L, Rickert C, Fowler AM, et al. STAT1-deficient mice spontaneously develop estrogen receptor α-positive luminal mammary carcinomas. Breast Cancer Res 2012; 14:R16; http://dx.doi.org/10.1186/bcr3100; PMID: 22264274
   PubMed Web of Science ®Google Scholar
• Schneckenleithner C, Bago-Horvath Z, Dolznig H, Neugebauer N, Kollmann K, Kolbe T, et al. Putting the brakes on mammary tumorigenesis: loss of STAT1 predisposes to intraepithelial neoplasias. Oncotarget 2011; 2:1043 - 54; PMID: 22185785
   PubMedGoogle Scholar
• Ursini-Siegel J, Hardy WR, Zuo D, Lam SH, Sanguin-Gendreau V, Cardiff RD, et al. ShcA signalling is essential for tumour progression in mouse models of human breast cancer. EMBO J 2008; 27:910 - 20; http://dx.doi.org/10.1038/emboj.2008.22; PMID: 18273058
   PubMed Web of Science ®Google Scholar
• Siegel PM, Ryan ED, Cardiff RD, Muller WJ. Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO J 1999; 18:2149 - 64; http://dx.doi.org/10.1093/emboj/18.8.2149; PMID: 10205169
   PubMed Web of Science ®Google Scholar
• Durbin JE, Hackenmiller R, Simon MC, Levy DE. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 1996; 84:443 - 50; http://dx.doi.org/10.1016/S0092-8674(00)81289-1; PMID: 8608598
   PubMed Web of Science ®Google Scholar
• Han W, Carpenter RL, Cao X, Lo HW. STAT1 gene expression is enhanced by nuclear EGFR and HER2 via cooperation with STAT3. Mol Carcinog 2012; In press http://dx.doi.org/10.1002/mc.21936; PMID: 22693070
   PubMed Web of Science ®Google Scholar
• Ursini-Siegel J. Beyond immune surveillance: Stat1 limits tumor growth in a cell-autonomous fashion. Cell Cycle 2011; 10:1348; http://dx.doi.org/10.4161/cc.10.9.15435; PMID: 21464617
   PubMed Web of Science ®Google Scholar
• Tenoever BR, Ng SL, Chua MA, McWhirter SM, García-Sastre A, Maniatis T. Multiple functions of the IKK-related kinase IKKepsilon in interferon-mediated antiviral immunity. Science 2007; 315:1274 - 8; http://dx.doi.org/10.1126/science.1136567; PMID: 17332413
   PubMed Web of Science ®Google Scholar
• Bonuccelli G, Castello-Cros R, Capozza F, Martinez-Outschoorn UE, Lin Z, Tsirigos A, et al. The milk protein α-casein functions as a tumor suppressor via activation of STAT1 signaling, effectively preventing breast cancer tumor growth and metastasis. Cell Cycle 2012; 11:3972 - 82; http://dx.doi.org/10.4161/cc.22227; PMID: 23047602
   PubMed Web of Science ®Google Scholar
• Khodarev NN, Minn AJ, Efimova EV, Darga TE, Labay E, Beckett M, et al. Signal transducer and activator of transcription 1 regulates both cytotoxic and prosurvival functions in tumor cells. Cancer Res 2007; 67:9214 - 20; http://dx.doi.org/10.1158/0008-5472.CAN-07-1019; PMID: 17909027
   PubMed Web of Science ®Google Scholar
• Khodarev NN, Roach P, Pitroda SP, Golden DW, Bhayani M, Shao MY, et al. STAT1 pathway mediates amplification of metastatic potential and resistance to therapy. PLoS One 2009; 4:e5821; http://dx.doi.org/10.1371/journal.pone.0005821; PMID: 19503789
   PubMedGoogle Scholar
• Weichselbaum RR, Ishwaran H, Yoon T, Nuyten DS, Baker SW, Khodarev N, et al. An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc Natl Acad Sci U S A 2008; 105:18490 - 5; http://dx.doi.org/10.1073/pnas.0809242105; PMID: 19001271
   PubMed Web of Science ®Google Scholar
• Thomas M, Finnegan CE, Rogers KM, Purcell JW, Trimble A, Johnston PG, et al. STAT1: a modulator of chemotherapy-induced apoptosis. Cancer Res 2004; 64:8357 - 64; http://dx.doi.org/10.1158/0008-5472.CAN-04-1864; PMID: 15548705
   PubMed Web of Science ®Google Scholar
• Harris LN, Yang L, Liotcheva V, Pauli S, Iglehart JD, Colvin OM, et al. Induction of topoisomerase II activity after ErbB2 activation is associated with a differential response to breast cancer chemotherapy. Clin Cancer Res 2001; 7:1497 - 504; PMID: 11410482
   PubMed Web of Science ®Google Scholar
• Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994; 330:1260 - 6; http://dx.doi.org/10.1056/NEJM199405053301802; PMID: 7908410
   PubMed Web of Science ®Google Scholar
• Pritchard KI, Shepherd LE, O’Malley FP, Andrulis IL, Tu D, Bramwell VH, et al, National Cancer Institute of Canada Clinical Trials Group. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 2006; 354:2103 - 11; http://dx.doi.org/10.1056/NEJMoa054504; PMID: 16707747
   PubMed Web of Science ®Google Scholar
• Magkou C, Giannopoulou I, Theohari I, Fytou A, Rafailidis P, Nomikos A, et al. Prognostic significance of phosphorylated STAT-1 expression in premenopausal and postmenopausal patients with invasive breast cancer. Histopathology 2012; 60:1125 - 32; http://dx.doi.org/10.1111/j.1365-2559.2011.04143.x; PMID: 22320867
   PubMed Web of Science ®Google Scholar
• Rajski M, Vogel B, Baty F, Rochlitz C, Buess M. Global gene expression analysis of the interaction between cancer cells and osteoblasts to predict bone metastasis in breast cancer. PLoS One 2012; 7:e29743; http://dx.doi.org/10.1371/journal.pone.0029743; PMID: 22235336
   PubMedGoogle Scholar